Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-02-21

Study Completion Date

2025-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main goal of this clinical trial is to learn about the safety and tolerability of GT-02287. The questions it aims to answer are:

* What medical problems do participants have when taking GT-02287?
* How is GT-02287 absorbed, distributed, and removed from the body of participants over time (pharmacokinetics)?
* Are there any biological effects of GT-02287 in blood and in cerebrospinal fluid that could be beneficial for people with Parkinson's disease?

Participants will:

* visit the clinic to assess if they qualify for the study (30-day Screening Period)
* if eligible, receive GT-02287 once a day every day for 90 days (90-day Open Label Treatment period)
* visit the clinic the first day of treatment, after the first 2 weeks of treatment, and every month during the 90-day Treatment Period.
* visit the clinic to assess how they are doing 14 days after the end of GT-02287 treatment (14-day Follow-Up Period).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease

NCT07280299

Parkinson Disease

NOT_YET_RECRUITING PHASE2

GM1 Ganglioside Effects on Parkinson's Disease

NCT00037830

Parkinson Disease

COMPLETED PHASE2

A Study of MK0657 in Parkinson's Disease Patients (0657-006)

NCT00505843

Parkinson's Disease

COMPLETED PHASE1

An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

NCT02889302

Spinocerebellar Degeneration

COMPLETED PHASE3

A Study to Examine APL-130277 in Patients With Parkinson's Disease

NCT02228590

Parkinson's Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This Phase 1b, 3-month, multicenter, open-label study of GT-02287 in participants with Parkinson's Disease with or without GBA1 mutations. The primary objective of the study is to evaluate the safety and tolerability of GT-02287. The study will also investigate pharmacokinetics (PK) and explore pharmacodynamic parameters in blood and CSF and effect of GT-02287 on scores from selected clinical scales. Approximately 20 participants will be enrolled to result in approximately 15 evaluable participants.

All participants will receive an oral dose of GT-02287 of 13.5 mg/kg/day (plus/minus 2 mg/kg/day) once a day for 90 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

single-arm. All participants receive the active molecule (once daily GT-02287 administration)

Group Type EXPERIMENTAL

GT-02287

Intervention Type DRUG

Dose of 13.5 mg/kg/day (plus/minus 2 mg/kg/day based on body weight) to be administered orally once a day for 90 days. Dosage form: powder in sachet (200 mg of GT-02287 per sachet) for reconstitution with a suspending agent

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GT-02287

Dose of 13.5 mg/kg/day (plus/minus 2 mg/kg/day based on body weight) to be administered orally once a day for 90 days. Dosage form: powder in sachet (200 mg of GT-02287 per sachet) for reconstitution with a suspending agent

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able and willing to provide written informed consent and be willing to comply with the requirements and restrictions of the study
* Any sex, ≥30 and ≤85 years of age
* Diagnosis of PD based on MDS criteria
* Within 7 years of PD diagnosis
* Body mass index of ≥18 and ≤40 kg/m2, and a body weight ≥45 kg and ≤120 kg
* Willing to provide a blood sample for PD-related genetic testing
* Hoehn \& Yahr 1-3, inclusive
* No severe motor fluctuations or disabling dyskinesias based on the investigator's clinical assessment
* Naïve to pharmacological treatment for PD or on stable PD medication for ≥3 months prior to Screening, including ≥4 weeks at the same dose(s) immediately before Screening
* Not pregnant or breastfeeding
* If participant is either of childbearing potential or produces potentially viable sperm, participant must agree to use 2 forms of contraception (barrier method and a second highly effective form of birth control/contraception, as defined in the protocol) if engaging in potentially reproductive intercourse (with a partner who produces potentially viable sperm or is of childbearing potential, respectively)
* Agreeing to not participate in another investigational study while taking part in this study
* For participants with known GBA1 mutations, presence of a GBA1 mutation that has been associated with an increased risk of PD

Exclusion Criteria

* Other neurological disorders, including but not limited to Alzheimer's disease, amyotrophic lateral sclerosis, frontotemporal dementia, progressive supranuclear palsy, corticobasal syndrome, Huntington's disease, multiple system atrophy, dementia with Lewy bodies, secondary (e.g. drug-induced) parkinsonism, multiple sclerosis, or epilepsy
* A history of Gaucher disease or homozygous for a GBA1 pathogenic variant known to be associated with GD or compound heterozygous for 2 alleles that are known to be associated with GD.
* Known PD-associated LRRK2 pathogenic variant or other PD-associated genetic mutations other than GBA1
* Dementia or a moderate cognitive impairment (score ≥17 on the Montreal Cognitive Assessment)
* Hypersensitivity to GT-02287 or any of its excipients
* Concomitant medications metabolized primarily by cytochrome P450 3A4 (CYP3A4) that have a narrow therapeutic window, concomitant medications that are substrates of breast cancer resistance protein and/or P-glycoprotein and that have a narrow therapeutic window, concomitant medications that are potent inhibitors or inducers of CYP3A4
* Use of dopamine antagonists (antipsychotics) or anticholinergic medications
* Concomitant disease including, but not limited to cardiovascular conditions, diabetes, autoimmune disease, cancer, active infectious disease, psychotic disorders and symptoms, depressive symptoms, drug and/or alcohol misuse as defined in the protocol
* Malabsorption or relevant disorder which may impact the absorption of GT-02287
* Clinically significant abnormalities in laboratory test
* Contraindications to lumbar puncture (LP)
* Blood donation \>500 mL within 3 months
* Unable to comply with restrictions on food products, smoking, and /or alcohol use as defined in protocol
* participation in any interventional clinical study within 3 months or 5 half-lives, whichever is longer, prior to Screening

Minimum Eligible Age

30 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No